亿帆医药(002019) - 2014年7月31日投资者关系活动记录表

Group 1: Company Overview - The company involved is Zhejiang Hangzhou Xinfuyuan Pharmaceutical Co., Ltd. [1] - The investor relations activity took place on July 31, 2014, at the company headquarters [1]. Group 2: Production and Operations - The supply and demand balance for calcium pantothenate products has been stable, but future price trends are difficult to predict [2]. - The PBS product line is not operating at full capacity due to slow market development, despite some market recovery [2]. - The company is managing production based on market sales to minimize losses from downtime [2]. Group 3: Major Asset Restructuring - The major asset restructuring was conditionally approved by the China Securities Regulatory Commission on July 3, 2014 [2]. - The company needs to submit additional materials regarding goodwill impairment risks and their impact on future performance [2][3]. - The company has complied with the requirements and submitted the necessary supplementary materials [3]. Group 4: Legal Matters - The company is involved in a trade secret infringement case with New Pharma, which was heard in the Shanghai High People's Court on July 3, 2014, with no verdict yet [3].